

Graham K Packham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6813242/publications.pdf>

Version: 2024-02-01

62
papers

3,699
citations

126858

33
h-index

133188

59
g-index

65
all docs

65
docs citations

65
times ranked

5516
citing authors

#	ARTICLE	IF	CITATIONS
1	B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells. Exploration of Targeted Anti-tumor Therapy, 2022, 3, 37-49.	0.5	2
2	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells. Cellular Signalling, 2022, 94, 110311.	1.7	5
3	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Blood, 2022, 140, 630-643.	0.6	14
4	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. Cellular Signalling, 2022, 96, 110358.	1.7	1
5	V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer. Molecular Cancer Therapeutics, 2021, 20, 739-748.	1.9	5
6	Synthesis of Carboxamide-Containing Tranylcyproline Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia. ChemMedChem, 2021, 16, 1316-1324.	1.6	5
7	KDM5 inhibition offers a novel therapeutic strategy for the treatment of <i>KMT2D</i> mutant lymphomas. Blood, 2021, 138, 370-381.	0.6	33
8	DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity. Scientific Reports, 2021, 11, 11676.	1.6	4
9	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. Blood, 2021, 138, 1570-1582.	0.6	9
10	Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells. Cellular and Molecular Life Sciences, 2021, 78, 6337-6349.	2.4	14
11	Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. Leukemia, 2020, 34, 462-477.	3.3	24
12	BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. Leukemia, 2020, 34, 640-644.	3.3	12
13	Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells. Clinical Cancer Research, 2020, 26, 1700-1711.	3.2	13
14	BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. Blood Advances, 2020, 4, 3316-3328.	2.5	24
15	Upregulation of epithelial metallothioneins by metal-rich ultrafine particulate matter from an underground railway. Metallomics, 2020, 12, 1070-1082.	1.0	6
16	Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms. , 2020, 1, 3-25.		7
17	Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors. , 2020, 1, 131-152.		13
18	Exploration of Targeted Anti-tumor Therapy: a contribution to the development of targeted therapies. , 2020, 1, 1-2.		0

#	ARTICLE	IF	CITATIONS
19	Metabolic targets of watercress and PEITC in MCF-7 and MCF-10A cells explain differential sensitisation responses to ionising radiation. <i>European Journal of Nutrition</i> , 2019, 58, 2377-2391.	1.8	20
20	Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. <i>Clinical Cancer Research</i> , 2019, 25, 2503-2512.	3.2	23
21	Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk. <i>Cancer Letters</i> , 2018, 421, 94-102.	3.2	22
22	CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM. <i>Blood Advances</i> , 2018, 2, 1869-1881.	2.5	15
23	LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models. <i>Cancer Cell International</i> , 2018, 18, 71.	1.8	19
24	Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with <i>In Vivo</i> Antitumor Activity. <i>Clinical Cancer Research</i> , 2018, 24, 4256-4270.	3.2	41
25	Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 16096.	18.1	363
26	Correction: Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17008.	18.1	82
27	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2313-2324.	3.2	51
28	Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. <i>Blood</i> , 2016, 128, 816-826.	0.6	54
29	Epigenetic modulators as therapeutic targets in prostate cancer. <i>Clinical Epigenetics</i> , 2016, 8, 98.	1.8	68
30	IL-4 enhances expression and function of surface IgM in CLL cells. <i>Blood</i> , 2016, 127, 3015-3025.	0.6	76
31	Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. <i>Blood</i> , 2016, 127, 449-457.	0.6	56
32	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. <i>Nature Genetics</i> , 2016, 48, 183-188.	9.4	160
33	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. <i>Gut</i> , 2016, 65, 977-989.	6.1	111
34	PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2 γ phosphorylation in established cell lines and primary human leukemia cells. <i>Oncotarget</i> , 2016, 7, 74807-74819.	0.8	7
35	A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells. <i>Oncotarget</i> , 2016, 7, 18851-18864.	0.8	10
36	High throughput imaging cytometer with acoustic focussing. <i>RSC Advances</i> , 2015, 5, 83206-83216.	1.7	25

#	ARTICLE	IF	CITATIONS
37	Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. <i>Blood</i> , 2015, 126, 1902-1910.	0.6	79
38	The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E μ -TCL1 mouse model. <i>Blood</i> , 2015, 125, 4032-4041.	0.6	34
39	Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, e265-e268.	1.7	9
40	Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma. <i>Blood</i> , 2015, 125, 3287-3296.	0.6	66
41	Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. <i>Oncotarget</i> , 2015, 6, 7262-7279.	0.8	35
42	The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. <i>Haematologica</i> , 2014, 99, 1138-1148.	1.7	87
43	The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 806-814.	0.8	78
44	The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. <i>Seminars in Hematology</i> , 2014, 51, 158-167.	1.8	42
45	Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and <i>Ex vivo</i> Fibroblasts. <i>Journal of Visualized Experiments</i> , 2014, , .	0.2	2
46	Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy. <i>Blood</i> , 2014, 123, 3277-3285.	0.6	32
47	Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. <i>Blood</i> , 2014, 124, 3101-3109.	0.6	34
48	Identification in CLL of circulating intracлонаl subgroups with varying B-cell receptor expression and function. <i>Blood</i> , 2013, 122, 2664-2672.	0.6	58
49	Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 119, 170-179.	0.6	85
50	Click JAHAs: conformationally restricted ferrocene-based histone deacetylase inhibitors. <i>MedChemComm</i> , 2012, 3, 61-64.	3.5	46
51	Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. <i>Cell Stress and Chaperones</i> , 2012, 17, 529-538.	1.2	44
52	Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines. <i>Journal of Pineal Research</i> , 2012, 53, 366-373.	3.4	78
53	B-cell receptor signaling in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 4313-4320.	0.6	331
54	Anti-angiogenic effects of dietary isothiocyanates: Mechanisms of action and implications for human health. <i>Biochemical Pharmacology</i> , 2011, 81, 327-336.	2.0	60

#	ARTICLE	IF	CITATIONS
55	Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18587-18592.	3.3	151
56	Inhibition of hypoxia inducible factor by phenethyl isothiocyanate. <i>Biochemical Pharmacology</i> , 2009, 78, 261-272.	2.0	53
57	The role of NF- κ B in lymphoid malignancies. <i>British Journal of Haematology</i> , 2008, 143, 3-15.	1.2	51
58	Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. <i>Blood</i> , 2007, 109, 4424-4431.	0.6	212
59	Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. <i>Immunology</i> , 2005, 114, 441-449.	2.0	139
60	Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. <i>Blood</i> , 2003, 101, 1087-1093.	0.6	279
61	The p36 isoform of BAG-1 is translated by internal ribosome entry following heat shock. <i>Oncogene</i> , 2001, 20, 4095-4100.	2.6	80
62	Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. <i>Oncogene</i> , 2001, 20, 6983-6993.	2.6	138